Switch theme
Sign up to access all valuation multiples
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the United States.
2013
133
Last FY Revenue $1.2M
Last FY EBITDA -$34.7M
$450M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Tanvex BioPharma achieved revenue of $1.2M and an EBITDA of -$34.7M.
Tanvex BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tanvex BioPharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.2M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.3M | XXX | XXX | XXX |
| Gross Margin | XXX | 24% | XXX | XXX | XXX |
| EBITDA | XXX | -$34.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -2996% | XXX | XXX | XXX |
| EBIT | XXX | -$45.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | -3912% | XXX | XXX | XXX |
| Net Profit | XXX | -$46.1M | XXX | XXX | XXX |
| Net Margin | XXX | -3984% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tanvex BioPharma's stock price is TWD 54 (or $2).
Tanvex BioPharma has current market cap of TWD 12.8B (or $427M), and EV of TWD 13.5B (or $450M).
See Tanvex BioPharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $450M | $427M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tanvex BioPharma has market cap of $427M and EV of $450M.
Tanvex BioPharma's trades at 389.4x EV/Revenue multiple, and -13.0x EV/EBITDA.
Equity research analysts estimate Tanvex BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tanvex BioPharma's P/E ratio is not available.
See valuation multiples for Tanvex BioPharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $427M | XXX | $427M | XXX | XXX | XXX |
| EV (current) | $450M | XXX | $450M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 389.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -13.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -10.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -9.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -10.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTanvex BioPharma's revenue per employee in the last FY averaged $9K, while opex per employee averaged $0.3M for the same period.
Tanvex BioPharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tanvex BioPharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tanvex BioPharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2996% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $9K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 129% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3052% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3936% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tanvex BioPharma acquired XXX companies to date.
Last acquisition by Tanvex BioPharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Tanvex BioPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tanvex BioPharma founded? | Tanvex BioPharma was founded in 2013. |
| Where is Tanvex BioPharma headquartered? | Tanvex BioPharma is headquartered in Taiwan. |
| How many employees does Tanvex BioPharma have? | As of today, Tanvex BioPharma has 133 employees. |
| Who is the CEO of Tanvex BioPharma? | Tanvex BioPharma's CEO is Mr. Lin-Cheng Chen. |
| Is Tanvex BioPharma publicy listed? | Yes, Tanvex BioPharma is a public company listed on TAI. |
| What is the stock symbol of Tanvex BioPharma? | Tanvex BioPharma trades under 6541 ticker. |
| When did Tanvex BioPharma go public? | Tanvex BioPharma went public in 2015. |
| Who are competitors of Tanvex BioPharma? | Similar companies to Tanvex BioPharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Tanvex BioPharma? | Tanvex BioPharma's current market cap is $427M |
| Is Tanvex BioPharma profitable? | Yes, Tanvex BioPharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
